Why the diagnosis must be specific
Premature ovarian insufficiency (POI) is diagnosed before age 40 and can involve irregular or absent periods, elevated gonadotropins, low estrogen and reduced ovarian function. Causes may include genetic, autoimmune, iatrogenic and unknown factors.
Low ovarian reserve, infertility and menopause are related concepts but are not identical. Accurate reproductive-endocrine diagnosis is essential.
What a regenerative pathway may involve
Regenerative approaches, including MSC-related research, have been investigated for ovarian function. Public clinical-translation information may exist in China, but international access, exact indications and evidence require direct confirmation.
This page is therefore labelled as research/evidence review rather than a confirmed treatment product.
Records needed for a meaningful review
- Reproductive endocrinology diagnosis
- FSH, LH, estradiol and AMH results with dates
- Menstrual history and age at symptom onset
- Pelvic ultrasound and antral follicle count
- Pregnancy and fertility-treatment history
- Genetic, autoimmune and chemotherapy/radiation history
- Current hormone therapy and other medication
- Fertility goals and time horizon
The reviewing institution may request additional tests after seeing the initial case summary.
Questions that affect eligibility
- Is the diagnosis true POI or reduced ovarian reserve?
- What is the likely cause?
- Is the goal symptom management, fertility or both?
- What standard fertility or hormone options remain?
- What outcome is supported by evidence?
- Is current clinical access available to foreign patients?
Evidence and limitations
Most regenerative approaches for POI remain investigational or early in clinical translation. Changes in biomarkers do not automatically mean restored fertility or live birth. Patients should ask which outcome was studied and how many pregnancies or births were reported, not only whether AMH changed.
Other treatment options to consider
Hormone replacement where appropriate, fertility counselling, assisted reproduction, donor eggs, genetic counselling, bone and cardiovascular health management may be relevant. A regenerative enquiry should not delay time-sensitive reproductive care.
Next step for an international patient
Send the confirmed diagnosis, hormone results, ultrasound, fertility history and treatment goal. We can assess whether a credible Chinese research or clinical pathway deserves direct verification.
Do not stop prescribed treatment, make irreversible travel plans or pay a medical fee until the responsible institution has reviewed the case and issued written instructions.